Press release
Ankylosing Spondylitis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Curious about the latest updates in the Ankylosing Spondylitis Pipeline? Click here to explore the therapies and trials making headlines @ Ankylosing Spondylitis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Ankylosing Spondylitis Pipeline Report
* On 01 August 2025, UCB Biopharma SRL conducted a study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
* DelveInsight's Ankylosing Spondylitis Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Ankylosing Spondylitis treatment.
* The leading Ankylosing Spondylitis Companies such as Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.
* Promising Ankylosing Spondylitis Therapies such as AK111, LNK01001, Secukinumab, Jaktinib, Bimekizumab, SHR-1314, and others.
Want to know which companies are leading innovation in Ankylosing Spondylitis? Dive into the full pipeline insights @ Ankylosing Spondylitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Ankylosing Spondylitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ankylosing Spondylitis Pipeline Report also highlights the unmet needs with respect to the Ankylosing Spondylitis.
Ankylosing Spondylitis Overview
Ankylosing Spondylitis (Bekhterev's Disease) is a type of arthritis that causes inflammation in the joints and ligaments of the spine. It may also affect peripheral joints like the knees, ankles, and hips. Normally, the joints and ligaments in the spine help us move and bend. If you have ankylosing spondylitis, the inflammation in the joints and tissues of the spine can cause stiffness. In severe cases, this may cause the vertebrae (bones in the spine) to fuse (grow together). When the vertebrae fuse, it can lead to a rigid and inflexible spine.
Ankylosing Spondylitis (Bekhterev's Disease) Emerging Drugs
* AK111: Akeso
AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through a combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.
* Jaktinib: Suzhou Zelgen Biopharmaceuticals
Jaktinib hydrochloride, developed by Suzhou Zelgen Biopharmaceuticals, is a novel Janus kinase (JAK) inhibitor. It acts by targeting tyrosine protein kinases JAK1, JAK2, and JAK3, thereby inhibiting the JAK signaling pathway. This mechanism of action (moA) is crucial in treating various diseases, including myelofibrosis, graft versus host disease, rheumatoid arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, autoimmune disorders, novel coronavirus pneumonia (COVID-19), and Ankylosing Spondylitis (Bekhterev's Disease). Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.
* VC005: Jiangsu Vcare Pharmatech
VC005 is a novel, highly efficient, and selective JAK1 inhibitor, as well as a second-generation inhibitor, independently developed by Jiangsu Vcare. By selectively inhibiting JAK1 kinase, decreasing the inflammatory response, and reducing the activation of immune cells, VC005 displays high potential for the treatment of inflammatory and autoimmune diseases. The in vitro kinase test results indicated that VC005 exhibited a lower inhibitory activity against JAK2 kinase compared to an approved dominant JAK inhibitor, Upadacitinib, thus it is expected to alleviate many safety concerns associated with excessive JAK2 kinase inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ankylosing spondylitis.
If you're tracking ongoing Ankylosing Spondylitis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Ankylosing Spondylitis Treatment Drugs [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Ankylosing Spondylitis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
* Ankylosing Spondylitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.
Ankylosing Spondylitis Companies
Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.
Ankylosing Spondylitis (Bekhterev's Disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Intramuscular
* Topical
Ankylosing Spondylitis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
From emerging drug candidates to competitive intelligence, the Ankylosing Spondylitis Pipeline Report covers it all - check it out now @ Ankylosing Spondylitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Ankylosing Spondylitis Pipeline Report
* Coverage- Global
* Ankylosing Spondylitis Companies- Jiangsu Vcare Pharmaceutical Technology, Lynk Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, UCB Biosciences, Akeso, NB Health Laboratory, Funpep, Shilpa Biologicals and others.
* Ankylosing Spondylitis Therapies- AK111, LNK01001, Secukinumab, Jaktinib, Bimekizumab, SHR-1314, and others.
* Ankylosing Spondylitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ankylosing Spondylitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Ankylosing Spondylitis Treatment landscape in this detailed analysis @ Ankylosing Spondylitis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Ankylosing Spondylitis (Bekhterev's Disease): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ankylosing Spondylitis (Bekhterev's Disease)- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Ankylosing Spondylitis (Bekhterev's Disease) Collaboration Deals
* Late Stage Products (Phase III)
* AK111: Akeso
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* VC005: Jiangsu Vcare Pharmatech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Ankylosing Spondylitis (Bekhterev's Disease) Key Companies
* Ankylosing Spondylitis (Bekhterev's Disease) Key Products
* Ankylosing Spondylitis (Bekhterev's Disease)- Unmet Needs
* Ankylosing Spondylitis (Bekhterev's Disease)- Market Drivers and Barriers
* Ankylosing Spondylitis (Bekhterev's Disease)- Future Perspectives and Conclusion
* Ankylosing Spondylitis (Bekhterev's Disease) Analyst Views
* Ankylosing Spondylitis (Bekhterev's Disease) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ankylosing-spondylitis-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ankylosing Spondylitis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4179848 • Views: …
More Releases from ABNewswire
The Boston Brown Coffee Company Expands Beverage Excellence with Premium Herbal …
The Boston Brown Coffee Company announces the addition of 12 thoughtfully selected premium herbal teas to its product lineup. Each tea has been chosen for its soothing qualities, vibrant aromas, and comforting flavors, providing customers with refined alternatives that complement the company's renowned coffee selection.
The Boston Brown Coffee Company has expanded beyond its coffee expertise to introduce a carefully curated collection of 12 premium herbal teas, marking a significant evolution…
Adsome Named Best AI Creative Production Agency for E-Commerce Brands in 2026
Stockholm-based Adsome solves the "Creative Starvation" bottleneck for global e-commerce brands by delivering high-performance, 100% digital ad creatives at scale following Meta's Andromeda algorithm update.
STOCKHOLM, SWEDEN - February 25, 2026 - Adsome, recognized as the best AI creative production agency for e-commerce brands, today announced the expansion of its performance-driven ad production service. The expansion meets surging demand from product brands across the Americas, Europe, and the Nordics by delivering…
Concrete Cleaning Professionals in Millsboro DE Provided by Hose Bros Inc for Ha …
Hose Bros Inc continues to serve Millsboro DE as a steady provider of concrete cleaning solutions, supporting the needs of Harbeson and Laurel residents. Through structured, reliable concrete cleaning services, the company provides consistent access to professional maintenance that prioritizes safety, functionality, and visual upkeep. Hose Bros Inc remains a trusted local resource, offering residents clear guidance and dependable execution for all their concrete surface needs.
Introduction: Concrete Cleaning in Millsboro…
Sky Vacations Unveils SV Prive: The Next Generation of Private Car Touring
Image: https://www.abnewswire.com/upload/2026/02/43245a867a0749dfca441b13931e87e1.jpg
New York City, NY - Building on decades of success as one of North America's most respected outbound luxury tour operators, Sky Vacations today announced the launch of SV Prive, a new collection of ultra-elevated private car journeys designed for travelers who expect more; more access, more intention, and more meaning in every mile.
With a presence that spans six continents, Sky Vacations has long been recognized as a trusted…
More Releases for Ankylosing
Ankylosing Spondylitis Market Treatment Advances and Global Growth Forecast
The Ankylosing Spondylitis (AS) Market focuses on therapies, diagnostics, and devices used for managing ankylosing spondylitis, a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. AS is characterized by pain, stiffness, and progressive spinal fusion, which can significantly impact patient quality of life. Market offerings include biologic therapies, non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), physiotherapy tools, and diagnostic imaging solutions.
Download Full PDF Sample Copy of Market…
Ankylosing Spondylitis Market Trends That Will Shape the Next Decade: Insights f …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Ankylosing Spondylitis Market Size By 2025?
The valuation of the ankylosing spondylitis sector has experienced robust expansion over the past few years, projected to advance from a figure of $5.9 billion in the year 2024 up to $6.34 billion by 2025, reflecting a compound annual…
Ankylosing Spondylitis Market Surges With The Growing Geriatric Population World …
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Ankylosing Spondylitis Market Size and Its Estimated Growth Rate?
The Ankylosing Spondylitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.…
Ankylosing Spondylitis Uncovered: Market Dynamics and Future Projections
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/2638
Introduction:
The global ankylosing spondylitis market has been on a steady rise, reflecting the growing awareness and prevalence of this inflammatory condition. With a remarkable market size of $5,140.94 million in 2020, the projections indicate a substantial leap to $8,110.59 million by 2030. Ankylosing spondylitis, often misunderstood, is a complex disorder that affects the spine's flexibility and posture, potentially leading to severe complications if not managed effectively.
Unveiling Ankylosing…
Ankylosing Spondylitis Market Overview With Detailed Analysis 2022-2028
According to Precision Business Insights (PBI), the latest report, ankylosing spondylitis market is expected to be valued at USD 5,460.5 million in 2022 which is expected to grow at a CAGR of 4.8% over 2022-2028. The primary factors that drive the market are the presence of biosimilars, usage of novel products, and increasing prevalence of ankylosing spondylitis.
View the detailed report description here - https://precisionbusinessinsights.com/market-reports/ankylosing-spondylitis-market/
Retail Pharmacy to Dominate the…
Ankylosing Spondylitis Market Challenges and Investment Opportunities by 2027
Allied Market Research published a report, titled, “Ankylosing Spondylitis Market: Global Opportunity Analysis and Industry Forecast 2020–2027.” According to the report, the global Ankylosing Spondylitis industry garnered $XX billion in 2019, and is expected to generate $xx billion by 2027, witnessing a CAGR of xx% from 2020 to 2027.
Click Here To Access Sample Report https://www.alliedmarketresearch.com/request-sample/10631
Major players analyzed include AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen…
